SCHELLER RICHARD H 4

What Happened

• Richard H. Scheller, a director of Maze Therapeutics (MAZE), was granted 18,000 derivative shares (reported as an award) on June 8, 2026. The filing reports an acquisition price of $0.00, indicating a compensatory grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-08; filing date: 2026-06-10 (filed within the Form 4 reporting window).
• Transaction type/code: A — Grant / Award (derivative securities).
• Shares awarded: 18,000; reported acquisition price: $0.00 (no cash paid at grant).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The award vests and becomes fully exercisable on the earlier of (i) the issuer’s 2027 annual stockholders meeting or (ii) June 8, 2027, subject to Scheller’s continued service (see footnote F1).
• Filing timeliness: Filed two days after the transaction date (timely under standard Form 4 rules).

Context

• This is a compensatory grant to a director (not an open-market purchase or sale). Such awards are common for board compensation and should be interpreted as compensation-related rather than a direct bullish or bearish trade signal. The award is subject to future vesting conditions, so it does not represent immediately tradable shares.